Latest chairman's letter re exciting new products reads the same as the 2003 report - all vague promises. In Dec 17 Dixon was enthusiastic about biologically active materials in pre filled syringes - products with much improved margins etc. This is all very misleading for investors/shareholders. This has the appearance that Medigard is stalling for some reason.
